1006865-30-0

Basic information

• Product Name: 1-benzyl-4-[4-((S)-3-methoxy-2-methyl-propoxy-methyl)-phenyl]-3-(R,S)-trityloxymethyl-1,2,3,6-tetrahydro-pyridine
• Synonyms: 1-benzyl-4-[4-((S)-3-methoxy-2-methyl-propoxy-methyl)-phenyl]-3-(R,S)-trityloxymethyl-1,2,3,6-tetrahydro-pyridine
• CAS NO: 1006865-30-0
• Molecular Weight: 637.862
• Mol File: 1006865-30-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-benzyl-4-[4-((S)-3-methoxy-2-methyl-propoxy-methyl)-phenyl]-3-(R,S)-trityloxymethyl-1,2,3,6-tetrahydro-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-4-[4-((S)-3-methoxy-2-methyl-propoxy-methyl)-phenyl]-3-(R,S)-trityloxymethyl-1,2,3,6-tetrahydro-pyridine(1006865-30-0)
• EPA Substance Registry System: 1-benzyl-4-[4-((S)-3-methoxy-2-methyl-propoxy-methyl)-phenyl]-3-(R,S)-trityloxymethyl-1,2,3,6-tetrahydro-pyridine(1006865-30-0)

Safety Data

• Hazardous Substances Data: 1006865-30-0(Hazardous Substances Data)

Upstream product

• 1006865-32-2 1-bromo-4-((S)-3-methoxy-2-methyl-propoxymethyl)-benzene 
• 589-17-3 p-bromobenzyl chloride 
• 911855-78-2 (R)-3-methoxy-2-methyl-propan-1-ol 
• 1006865-31-1 1-benzyl-4-[4-((S)-3-methoxy-2-methyl-propoxymethyl)-phenyl]-3-(R,S)-trityloxy-methyl-piperidin-4-(R,S)-ol 

Downstream Products

• 1006865-29-7 (rac-3R,4R,5S)-1-benzyl-4-[4-((S)-3-methoxy-2-methyl-propoxymethyl)-phenyl]-5-trityloxymethyl-piperidin-3-ol 
• 1018478-38-0 (3R,4R,5S)-1-benzyl-3-hydroxy-4-[4-((S)-3-methoxy-2-methyl-propoxymethyl)-phenyl]-5-trityloxymethyl-piperidinium (S)-carboxy-phenyl-methanolate 
• 1006901-40-1 1-benzyl-4-[4-((S)-3-methoxy-2-methyl-propoxymethyl)-phenyl]-5-trityloxymethyl-piperidin-3-ol 

Relevant articles and documents

SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS

Described are compounds of the general formula (I), and pharmaceutically acceptable salt thereof, in which R1 has the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibi

Organic compounds

The present invention relates to substituted piperidines of the general formula (I), where R1, R2, R3, R4, R5, Q and X have the definitions elucidated in more detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors. Moreover, the enzymatic substrate portion of the compound is simultaneously a substrate for a membrane transporter.